Aridis Pharmaceuticals (NASDAQ: ARDS) is one of 547 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Aridis Pharmaceuticals to related businesses based on the strength of its institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.
Earnings & Valuation
This table compares Aridis Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aridis Pharmaceuticals||$2.76 million||-$22.10 million||-1.37|
|Aridis Pharmaceuticals Competitors||$2.17 billion||$230.01 million||-3.51|
Aridis Pharmaceuticals’ rivals have higher revenue and earnings than Aridis Pharmaceuticals. Aridis Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current recommendations and price targets for Aridis Pharmaceuticals and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aridis Pharmaceuticals Competitors||4532||12988||27628||994||2.54|
Aridis Pharmaceuticals presently has a consensus price target of $30.60, indicating a potential upside of 218.09%. As a group, “Pharmaceutical preparations” companies have a potential upside of 57.62%. Given Aridis Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Aridis Pharmaceuticals is more favorable than its rivals.
Institutional and Insider Ownership
0.2% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 14.9% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Aridis Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aridis Pharmaceuticals Competitors||-1,760.46%||-120.17%||-28.09%|
Aridis Pharmaceuticals beats its rivals on 7 of the 12 factors compared.
About Aridis Pharmaceuticals
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.